“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study
- 30 November 2009
- journal article
- research article
- Published by Elsevier BV in Respiratory Medicine
- Vol. 103 (11), 1633-1642
- https://doi.org/10.1016/j.rmed.2009.06.014
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The use of omalizumab in asthmaPrimary Care Respiratory Journal, 2008
- Global strategy for asthma management and prevention: GINA executive summaryEuropean Respiratory Journal, 2008
- Severe serum sickness–like syndrome after omalizumab therapy for asthmaJournal of Allergy and Clinical Immunology, 2007
- The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UKPrimary Care Respiratory Journal, 2007
- Are the Asthma Guideline Goals Achieved in Daily Practice? A Population-Based Study on Treatment Adequacy and the Control of AsthmaInternational Archives of Allergy and Immunology, 2005
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthmaAllergy, 2004
- Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research DesignsThe New England Journal of Medicine, 2000
- A Comparison of Observational Studies and Randomized, Controlled TrialsThe New England Journal of Medicine, 2000
- Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.Thorax, 1992